Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples